← Browse by Condition
Medical Condition

idh1 mutant glioma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for idh1 mutant glioma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 3
1
Top Sponsors
Nuvation Bio Inc. 1 trial

Recruiting Clinical Trials

NCT05303519 Phase 3
Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Enrollment
365 pts
Location
United States, Austr...
Sponsor
Nuvation Bio Inc.
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology